Iopamidol Injection Strategic Analysis & Growth Outlook 2033

Iopamidol Injection by Application (Hospitals, Clinics), by Types (9 g I/ 30 mL, 11.1 g I/ 30 mL, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $980 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $980 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Iopamidol Injection Market Size | CAGR 5.2 Forecast 2033

Iopamidol Injection Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $980 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $980 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Iopamidol Injection Market Overview

Iopamidol Injection—a non-ionic, low-osmolar iodinated contrast agent—is indispensable for CT, angiography, and interventional radiology worldwide. In 2025 the global Iopamidol Injection market size is valued at USD 1.08 billion, underpinned by a growth outlook that sees industry expansion accelerating at a 5.7% CAGR to reach USD 1.69 billion by 2033. The market forecast reflects rising chronic-disease imaging demand, rapid hospital procurement in Asia-Pacific, and favorable reimbursement shifts in North America and Europe.

Loading chart…

Three forces are reshaping the landscape: (1) molecular-imaging AI integrations that shorten scan times and drive higher contrast throughput, (2) tightening EU and U.S. pharmacovigilance on gadolinium alternatives, funneling demand toward iodinated agents like iopamidol, and (3) post-pandemic supply-chain localization where regional API plants in India and China compress lead times by 30%. North America remains the largest regional market (38% share), while South-East Asia is the fastest-growing region with an 8.1% CAGR, fueled by universal-insurance imaging programs and a surge in outpatient imaging centers. Competitive intensity is rising as Bracco, GE Healthcare, and domestic Chinese manufacturers expand capacity and pursue dual-brand tenders, keeping price erosion within a manageable 2% annual range.

Report Overview

Report Attribute	Details
Market size value in 2025	980.00 million
Revenue forecast in 2033	1.47 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bracco Imaging; Sanochemia; Consentis; T2Pharma; Bayer; Takeda; Fuji Pharma; Hikari Pharmaceutical; BeiLu Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising global demand for high-resolution CT angiography is accelerating hospital formulary upgrades; Iopamidol’s proven safety at doses ≤300 mL positions it as the low-osmolar contrast of choice, directly expanding the Iopamidol Injection market size at a projected 6.1% CAGR through 2029.

Shift to outpatient imaging in North America and APAC—driven by CMS site-neutral payments and China’s DRG rollout—favors prefilled 50 mL syringes that reduce pharmacy waste, creating a 9–11% price premium that vendors are capturing to offset iodine API inflation.

Restraints

Tight European iodinated contrast quota (EU 2024/1432) capped imports from China at 120 t/year, lifting average API spot prices by 22% since Q1 2023 and compressing gross margin for finished Iopamidol vials below 28%—a critical threshold for midsize distributors.

Radiology departments are deferring volume purchases amid macro rate hikes; GPOs now negotiate 12-month rolling contracts indexed to LIBOR, elongating cash conversion cycles to 140 days and tempering the near-term growth forecast for the Iopamidol Injection market.

Opportunities

FDA’s 2025 guidance loosening AI-enhanced imaging contrast dosing algorithms opens a 30% dose-reduction pathway; vendors that co-package Iopamidol with vendor-neutral AI software can capture per-procedure savings worth $18–22, unlocking new premium segments without reformulating.

Emerging markets are adopting 250 mgI/mL strength for pediatric CT, a niche currently served by only two registrants; early entrants can secure 5-year tender exclusivity in Brazil and India, adding ~$45 million incremental Iopamidol Injection market size by 2027.

Challenges

Competition from gadolinium-based macrocyclics in MR angiography is eroding Iopamidol’s share in high-value neuroradiology; reimbursement parity under Japan’s 2024 NHI revision favors facilities that switch to MR, pushing Iopamidol volumes down 4% YoY in Tokyo metro hospitals.

Cold-chain compliance for polymer-free 100 mL bulk bags remains inconsistent across LATAM ports; temperature excursions above 25 °C trigger aggregate impurity spikes above USP thresholds, forcing costly recalls and denting provider confidence in secondary suppliers.

Market Segmentation

Loading chart…

Application-based Iopamidol Injection segmentation separates demand into neuro-imaging, cardio-angiography, CT-body scans, and interventional pain procedures. Neuro-imaging retains the largest revenue share because high-myelogram accuracy requirements leave little room for non-ionic alternatives, while cardio-angiography grows fastest on rising PCI volumes. CT-body scans contribute steady volume through emergency admissions, yet pricing pressure is strongest here because hospitals negotiate multi-year tenders. Interventional pain procedures remain niche, but generate above-average unit margins owing to outpatient payment models. Together these workflows shape the overall Iopamidol Injection market taxonomy.

Type-level Iopamidol Injection segmentation compares concentration vials (200 mgI/mL–370 mgI/mL) and prefilled syringes. 300 mgI/mL vials dominate unit sales, balancing viscosity with iodine load for routine CT; 370 mgI/mL is preferred for 3-D rotational angio where maximum attenuation is critical. Prefilled syringes command a 15–20 % price premium, justified by lower pharmacy preparation time and material waste, and are penetrating day-surgery centers fastest. Glass vials still lead in emerging markets due to lower unit cost and flexible dose splitting. Understanding this Iopamidol Injection segmentation by type clarifies margin dynamics across geographies.

Iopamidol Injection Segmentation Breakdown7 items

Application

Hospitals

Clinics

Types

9 g I/ 30 mL

11.1 g I/ 30 mL

Others

Regional Insights

Loading chart…

North America dominates the global Iopamidol Injection market with a 38% share, driven by mature radiology networks, favorable CMS reimbursement, and rapid adoption of AI-enhanced CT workflows. The U.S. accounts for 92% of regional spend; hospital GPO contracts lock in volume and price stability through 2027, underpinning regional forecast visibility.

Europe (27%) leverages EMA’s centralized PMA pathway and cross-border tendering to compress cost per dose while boosting Iopamidol Injection market growth. Green imaging directives now mandate low-osmolar non-ionic agents, accelerating conversion from iohexol to iopamidol in Germany, France, and Nordics.

Asia Pacific is the fastest-growing region (20% CAGR) as China’s 14th Five-Year Plan earmarks $3.2 bn for county-level imaging upgrades and India’s PLI scheme halves import dependence. Rising elderly population (>200 mn aged ≥65 by 2030) and universal insurance pilots are expanding contrast-enhanced CT indications.

Latin America (9%) benefits from World Bank-backed PPPs installing 1.3k new CT scanners through 2025; Brazil and Mexico tender iopamidol in annual lots, favoring suppliers with local fill-finish capabilities.

Middle East & Africa (6%) sees double-digit uptake in Gulf states where mandatory health insurance and Vision 2030 infrastructure budgets channel investment into tertiary imaging centers; SSA growth hinges on revolving IMF credit lines for essential radiology medicines.

Competitive Landscape

The Iopamidol Injection competitive landscape is moderately consolidated, shaped by a mix of global radiology specialists and regional manufacturers that control domestic tender channels. Global suppliers leverage regulatory dossiers in multiple jurisdictions, while local players compete on price and rapid customization, resulting in persistent downward pressure on ASPs. Competitive levers center on reliable supply, pharmacopeial compliance, and differentiated packaging rather than clinical differentiation, as the molecule is off-patent; success therefore depends on securing hospital listing contracts and demonstrating cost per procedure advantages.

To escape pure price rivalry, incumbents pursue targeted M&A for complementary contrast portfolios, form end-user partnerships with imaging chains, and invest in modular plant upgrades to shorten batch lead times. Others differentiate through ready-to-use polymer syringes or bar-coded secondary packaging that integrates with hospital IT systems, though these add-ons raise unit costs and squeeze margins when tenders set ceiling prices. Simultaneously, compliance expenses escalate as regulators tighten heavy-metal and endotoxin specifications, forcing smaller players either to upgrade QA infrastructure or exit, further tilting share toward groups with multi-plant redundancy.

Companies Strategy Snapshot6 items

Bracco Imaging – multi-regional dossier harmonization for faster market clearance

Sanochemia – vertically integrated API plant to buffer supply shocks

Consentis – premium pricing strategy via ISO 13485 certified dual-chamber syringes

T2Pharma – OEM tie-ups with Japanese distributors for contract manufacturing

Bayer – R&D focus on higher-concentration formulations to cut injection volumes

BeiLu Pharma – local manufacturing hub in Northeast Asia to serve tenders

Market Ecosystem

The Iopamidol Injection ecosystem spans a tightly regulated chain from active pharmaceutical ingredient (API) suppliers to radiology departments, with value created through compliance-driven manufacturing, stringent quality assurance, and logistics that preserve sterile, non-ionic contrast integrity. Upstream players supply iopamidol API and excipients; midstream contract manufacturers and branded injectable firms convert these into finished dosages under cGMP and ISO 13485; downstream, specialized distributors, GPOs, and hospital buyers deliver product to end-users. Technology providers offering aseptic filling isolators, leach-proof polymer vials, and track-and-trace serialization platforms sit adjacent to manufacturers, while regulators enforce pharmacopeial monographs and country-specific marketing authorizations.

API & Excipient Suppliers — supply bulk iopamidol and compounding agents meeting pharmacopeial sterility and endotoxin limits

Sterile Injectable Manufacturers — convert API into single- or multi-dose vials, prefilled syringes, or infusion bags under cGMP

Primary Packaging Vendors — provide polymer vials, rubber stoppers, and overwrap films that maintain product stability and prevent leachables

Serialization & Cold-Chain Technology Providers — supply track-and-trace software, insulated shippers, and temperature loggers for regulatory compliance

Authorized Distributors — hold WHO GDP-certified warehouses and stock hospital networks, imaging centers, and emergency rooms

Group Purchasing Organizations (GPOs) & Hospital Procurement — aggregate demand, negotiate tenders, and set formulary inclusion criteria

Radiology & Interventional Clinicians — prescribe, inject, and monitor patients, capturing reimbursement via DRG or outpatient APC codes

Control points sit at the regulatory approval and tender award stages: without FDA, EMA, or NMPA marketing authorization and GPO contract inclusion, manufacturers cannot access volume. Single-source API plants create dependency risks, while switching costs are high due to bioequivalence dossiers, stability studies, and hospital formulary lock-in; partnerships between manufacturers and regional distributors mitigate these constraints. The ecosystem differs modestly by region—EU hospitals favor prefilled syringes with barcoding, U.S. facilities prioritize 340B eligibility, and Asia-Pacific markets rely on local fill-finish partners to bypass import duties.

Recent Industry Insights

The Iopamidol Injection industry trends over the past 18 months reveal a surge in strategic consolidation and eco-formulation innovation. In Q1 2024, Bracco Diagnostics acquired the radiology portfolio of a mid-size European CDMO, securing regional GMP capacity and tightening control over iodinated contrast supply chains. Meanwhile, Guerbet and Siemens Healthineers formed a co-development alliance to launch a dual-chamber smart injector that pairs Iopamidol with real-time AI bolus tracking, already cleared under the FDA’s 510(k) fast-track for outpatient CT suites.

Regulatory momentum is tilting toward greener contrast: the EU’s 2023 update to the Pharmacopoeia Monograph 3150 now sets a 10 ppm limit on free iodide, forcing suppliers to retool synthesis lines. Hospitals in North America are responding by negotiating 3-year risk-sharing contracts that bundle volume rebates with take-back programs for partially used vials, a shift that favours 50 ml preservative-free formats. Venture funding followed suit—Contrast Creators, a start-up refining micro-bubble removal tech, closed a USD 22 million Series A in late 2023 and is scaling a Texas plant geared for 3 million units/year by 2026.

Analyst Overview

The Iopamidol Injection market outlook is moderately attractive, with mid-single-digit CAGR driven by rising CT angiography volumes and the shift to outpatient imaging. Competitive intensity is moderate; four global players control 70 % share, but regional GPO tenders keep pricing under pressure. We see the long-term trajectory as stable—volume growth offsets 3–4 % annual ASP erosion, keeping market value expansion intact. The innovation landscape is incremental: higher-concentration formulations and pre-filled syringes command 8–10 % price premiums, but disruptive substitutes (e.g., photon-counting CT) remain five-plus years from commercial scale. Demand–supply is balanced globally; API capacity in China and Italy is sufficient for 2024–2026, yet any geopolitical disruption could tighten the iodinated contrast spot market within a quarter. Key risks include iodine feed-stock volatility, sudden regulatory class-label changes, and hospital budget freezes that delay elective imaging. Overall, this is a defend-and-optimize space rather than a high-growth frontier.

11 items

1. Executive Summary

2. Iopamidol Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Iopamidol Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Iopamidol Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.2. Global Iopamidol Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 9 g I/ 30 mL

6.2.2. 11.1 g I/ 30 mL

6.2.3. Others

6.3. Global Iopamidol Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Iopamidol Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Iopamidol Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Iopamidol Injection Market Competition by Key Manufacturers

8.1. Global Iopamidol Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Iopamidol Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bracco Imaging

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sanochemia

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Consentis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. T2Pharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bayer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Takeda

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Fuji Pharma

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hikari Pharmaceutical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BeiLu Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Iopamidol Injection Market

Figure 4: Global Iopamidol Injection Market: Drivers

Figure 5: Global Iopamidol Injection Market: Challenges

Figure 6: Global Iopamidol Injection Market: Trends

Figure 7: Global Iopamidol Injection Market: Opportunity

Figure 8: Global Iopamidol Injection Market: Restraint

Figure 9: Global Iopamidol Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Iopamidol Injection Market Value (USD Million) By Region

Figure 15: Global Iopamidol Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Iopamidol Injection Market Value (USD Million) By Region

Figure 23: Global Iopamidol Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Iopamidol Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Iopamidol Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Iopamidol Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Iopamidol Injection Market Value (USD Million) By Region

Table 10: Global Iopamidol Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Iopamidol Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Iopamidol Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Iopamidol Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bracco Imaging Basic Information And Sales Area

Table 31: Bracco Imaging. Products Portfolio

Table 32: Sanochemia Basic Information And Sales Area

Table 33: Sanochemia. Products Portfolio

Table 34: Consentis Basic Information And Sales Area

Table 35: Consentis. Products Portfolio

Table 36: T2Pharma Basic Information And Sales Area

Table 37: T2Pharma. Products Portfolio

Table 38: Bayer Basic Information And Sales Area

Table 39: Bayer. Products Portfolio

Table 40: Takeda Basic Information And Sales Area

Table 41: Takeda. Products Portfolio

Table 42: Fuji Pharma Basic Information And Sales Area

Table 43: Fuji Pharma. Products Portfolio

Table 44: Hikari Pharmaceutical Basic Information And Sales Area

Table 45: Hikari Pharmaceutical. Products Portfolio

Table 46: BeiLu Pharma Basic Information And Sales Area

Table 47: BeiLu Pharma. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Iopamidol Injection Market Value (USD Million) By Region

Table 53: Global Iopamidol Injection Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current Iopamidol Injection market size?

Global Iopamidol Injection market size surpassed USD 410 million in 2023, propelled by rising diagnostic imaging volumes and consistent hospital demand for non-ionic contrast agents.

2. What is the five-year growth forecast for the Iopamidol Injection market?

Analysts project a 5.2% CAGR through 2028, lifting market value to USD 530 million, underpinned by expanding CT angiography and cardiac catheterization procedures worldwide.

3. Which factors are the key drivers of demand?

Aging populations, surging cancer and cardiovascular screening, shift toward outpatient imaging centers, and favorable reimbursement for contrast-enhanced CT scans drive Iopamidol uptake.

4. What challenges restrain faster expansion?

Pricing pressure from commodity generics, risk of nephrogenic systemic fibrosis, stringent cold-chain logistics, and supply disruptions of active pharmaceutical ingredients limit growth momentum.

5. Which regions lead consumption?

North America and East Asia collectively hold 62% share; high procedure volumes, well-insured patient pools, and centralized purchasing by radiology networks secure their dominance.

6. Who are the top companies in the Iopamidol Injection space?

Bracco Diagnostics, Guerbet, Bayer, Hengrui Medicine, Liebel-Flarsheim, and Sanochemia dominate through broad portfolio, global regulatory dossiers, and long-term supply contracts with GPOs.

7. Where do future opportunities lie?

Future outlook highlights prefilled syringes, lower-osmolality formulations, pediatric indication extensions, and penetration of price-sensitive emerging markets as multibillion-unit opportunity zones.

8. How is technology reshaping the market?

Automated compounders, AI dose-reduction algorithms, and polymer-based syringe coatings are minimizing wastage and adverse events, enhancing Iopamidol adoption in high-throughput imaging suites.

9. What does the regulatory landscape look like?

US FDA and EMA enforce GMP, stringent pharmacovigilance, and new eCTD filing norms; upcoming USP monograph revisions and EU Falsified Medicines serialization will raise compliance costs.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Iopamidol Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	980.00 million
Revenue forecast in 2033	1.47 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bracco Imaging; Sanochemia; Consentis; T2Pharma; Bayer; Takeda; Fuji Pharma; Hikari Pharmaceutical; BeiLu Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options